ASTEC
Astec LifeSciences share price & financials
- Price
- ₹690.75
- Market cap
- ₹1.6k Cr
- Sector
- Chemicals
What Astec LifeSciences Limited does
Astec LifeSciences manufactures agrochemical active ingredients (technicals), bulk formulations and intermediates, using multi-step synthesis to handle complex chemical reactions. It sells through two business lines: an Enterprise business selling its own technicals/formulations to domestic and export customers, and a Contract Development and Manufacturing (CDMO) business that makes agrochemical products on contract for global crop-protection innovators. It holds a leadership position in triazole fungicides in India and globally, and is a majority-owned subsidiary of Godrej Agrovet Limited (part of the Godrej Group).
Segments
- Agrochemicals
- Manufacturing plants
- 4 multipurpose, multi-product plants, all in Mahad, Maharashtra
- R&D centres
- 1 (Adi Godrej Center for Chemical Research & Development, Rabale, Maharashtra)
- Export countries
- 18 countries including USA, Europe, West Asia, Southeast Asia, Latin America and Africa
- Market position
- Leader in triazole fungicides, in India and globally
- Regular employees
- 554
- Dedicated facility
- Herbicide manufacturing facility with high-potency blocks and zero-liquid-discharge design, commissioned FY24-25 for CDMO business
Quarterly results
Q1 FY27: revenue down 7.7%, net profit up 42.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 99 | 94 | 120 | 91 | 74 −25% | 125 +33% | 159 +33% | 84 −8% |
| EBITDA | -20 | -6 | 6 | -11 | -7 +65% | 4 +167% | 9 +50% | -1 +91% |
| Net profit | -39 | -40 | -16 | -33 | -24 +38% | -16 +60% | -8 +50% | -19 +42% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −17.9% 1Y
1Y: ₹852.45 on 10 Sept 2025 → ₹699.8. High ₹918.75 (25 Nov 2025), low ₹521.85 (23 Mar 2026).
Financials, as filed
Revenue fell 10.6% a year over 3 years, FY23 to FY26. Operating margin narrowed to -1.1%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹628 Cr | ₹459 Cr | ₹382 Cr | ₹449 Cr |
| Operating profit | ₹75 Cr | ₹-5 Cr | ₹-66 Cr | ₹-5 Cr |
| Operating margin | 12.0% | -1.1% | -17.3% | -1.1% |
| Interest | ₹21 Cr | ₹25 Cr | ₹36 Cr | ₹34 Cr |
| Depreciation | ₹34 Cr | ₹36 Cr | ₹43 Cr | ₹45 Cr |
| Net profit | ₹25 Cr | ₹-46 Cr | ₹-135 Cr | ₹-81 Cr |
| Net margin | 4.0% | -10.0% | -35.3% | -18.0% |
| Cash from operations | ₹74 Cr | ₹10 Cr | ₹-8 Cr | ₹-81 Cr |
| Free cash flow | ₹-42 Cr | ₹-125 Cr | ₹-24 Cr | ₹-85 Cr |
| ROCE | 8.0% | -4.0% | -13.0% | -5.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹22 Cr | ₹22 Cr |
| Reserves | ₹289 Cr | ₹376 Cr | ₹399 Cr | ₹349 Cr | ₹392 Cr | ₹368 Cr |
| Borrowings | ₹188 Cr | ₹280 Cr | ₹341 Cr | ₹494 Cr | ₹367 Cr | ₹449 Cr |
| Other liabilities | ₹182 Cr | ₹221 Cr | ₹219 Cr | ₹111 Cr | ₹102 Cr | ₹102 Cr |
| Total liabilities | ₹678 Cr | ₹897 Cr | ₹979 Cr | ₹974 Cr | ₹883 Cr | ₹941 Cr |
| Fixed assets | ₹213 Cr | ₹340 Cr | ₹318 Cr | ₹386 Cr | ₹500 Cr | ₹459 Cr |
| Capital work in progress | ₹116 Cr | ₹23 Cr | ₹127 Cr | ₹165 Cr | ₹0 Cr | ₹20 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹349 Cr | ₹534 Cr | ₹533 Cr | ₹423 Cr | ₹383 Cr | ₹462 Cr |
| Total assets | ₹678 Cr | ₹897 Cr | ₹979 Cr | ₹974 Cr | ₹883 Cr | ₹941 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters added +1.10 pp while DIIs trimmed −0.93 pp. The shareholder count grew 7% to 19,889.
- Promoters
- 72.0%
- FIIs
- 0.0%
- DIIs
- 3.3%
- Public
- 24.7%
Since Jun 2025
- Promoters +1.10 pp
- DIIs −0.93 pp
- Public −0.15 pp
How it drifted, 12 quarters
Over this window DIIs fell from 10.2% to 3.3% — −6.8 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 66.8%, FIIs 1.3%, DIIs 10.2%, Public 21.7%.Dec '23: Promoters 66.8%, FIIs 1.3%, DIIs 9.7%, Public 22.2%.Mar '24: Promoters 66.8%, FIIs 1.3%, DIIs 7.9%, Public 24.1%.Jun '24: Promoters 66.8%, FIIs 1.0%, DIIs 3.4%, Public 28.9%.Sep '24: Promoters 66.7%, FIIs 0.5%, DIIs 4.5%, Public 28.2%.Dec '24: Promoters 66.7%, FIIs 1.2%, DIIs 5.4%, Public 26.6%.Mar '25: Promoters 70.9%, FIIs 0.3%, DIIs 4.3%, Public 24.5%.Jun '25: Promoters 70.9%, FIIs 0.0%, DIIs 4.3%, Public 24.8%.Sep '25: Promoters 72.4%, DIIs 4.0%, Public 23.6%.Dec '25: Promoters 72.0%, FIIs 0.0%, DIIs 3.2%, Public 24.8%.Mar '26: Promoters 72.0%, FIIs 0.0%, DIIs 3.3%, Public 24.7%.Jun '26: Promoters 72.0%, FIIs 0.0%, DIIs 3.3%, Public 24.7%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- NRG Enterprises LLP newly disclosed 0.00% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Astec LifeSciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Godrej Agrovet Limited | 67.03% | unchanged |
| Nippon Life India Trustee Ltd-A/C Nippon India Large Cap Fund Mutual fund | 2.36% | unchanged |
| Nadir Burjor Godrej | 1.82% | unchanged |
| Ashok Vishwanath Hiremath | 1.31% | unchanged |
| Ajay Kumar Aggarwal - 2 | 1.05% | −0.25 pp |
| Pirojsha Adi Godrej | 0.61% | unchanged |
| Nisaba Godrej | 0.61% | unchanged |
| Tanya Arvind Dubash | 0.61% | unchanged |
| Godrej International Trading & Investment Pte. Ltd. | 0.00% | unchanged |
| Godrej Properties Limited | 0.00% | unchanged |
| Godrej Realty Private Limited | 0.00% | unchanged |
| Godrej Garden City Properties Private Limited | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in ASTEC
Filings to Aug 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹30 Cr
- 1 schemes
- Biggest holder
- Nippon India Small Cap Fund
- ₹30 Cr · 0.0% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹30 Cr | held | Jun '22 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- -60%
- vs est. average cost
- Held by funds
- ₹30 Cr
- 1 schemes · ≈ 2.3% of the company
Shares held by these funds −27%
Aug '23 5.27 L shares Jul '26
Learn to analyse Astec LifeSciences Limited
Guides on how to read this kind of business and the numbers that matter.